Igonin Anton A, Armstrong Victor W, Shipkova Maria, Lazareva Natalya B, Kukes Vladimir G, Oellerich Michael
Department of Clinical Pharmacology, I.M. Sechenov Medical Academy, Moscow, Russia.
Clin Biochem. 2004 Mar;37(3):204-9. doi: 10.1016/j.clinbiochem.2003.11.001.
To assess the influence of empirical antibacterial therapy on systemic inflammatory response in patients with severe community-acquired pneumonia (CAP).
Thirty consecutive patients with CAP meeting systemic inflammatory response syndrome (SIRS) criteria were recruited into this study. Blood samples for measurement of interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10) and C-reactive protein (CRP) concentrations were drawn on days 1, 3, 5, 7 and 10. For analysis, these patients were divided into two subgroups according to British Thoracic Society (BTS) severity score and to clinical response to the initial antibacterial therapy.
In the group with severe CAP (n= 15), serum concentrations of IL-6 (P = 0.0001), IL-8, (P = 0.001), IL-10 (P = 0.0001) and CRP (P = 0.0001) were significantly higher compared to patients from the non-severe group (n= 15). IL-6 presented with a sharp decrease between days 1 and 3 in non-responders with severe CAP (P = 0.004). IL-6 concentrations on day 1 were significantly associated with a response to empirical antibacterial treatment by day 3.
Despite the absence of a clinical response to empirical antibacterial treatment as assessed by conventional clinical parameters on day 3 in patients with severe CAP meeting SIRS criteria, there was a marked reduction in the degree of the systemic inflammatory response as reflected by IL-6 levels.
评估经验性抗菌治疗对重症社区获得性肺炎(CAP)患者全身炎症反应的影响。
连续纳入30例符合全身炎症反应综合征(SIRS)标准的CAP患者进行本研究。在第1、3、5、7和10天采集血样,测定白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、白细胞介素-10(IL-10)和C反应蛋白(CRP)浓度。为进行分析,根据英国胸科学会(BTS)严重程度评分和对初始抗菌治疗的临床反应,将这些患者分为两个亚组。
与非重症组(n = 15)患者相比,重症CAP组(n = 15)血清IL-6(P = 0.0001)、IL-8(P = 0.001)、IL-10(P = 0.0001)和CRP(P = 0.0001)浓度显著更高。在重症CAP无反应者中,IL-6在第1天至第3天急剧下降(P = 0.004)。第1天的IL-6浓度与第3天对经验性抗菌治疗的反应显著相关。
尽管符合SIRS标准的重症CAP患者在第3天根据传统临床参数评估对经验性抗菌治疗无临床反应,但IL-6水平反映出全身炎症反应程度有明显降低。